GlassScriptPhysician profile
Francesca Lewis
NPI 1558598698
$175,403.80
in general payments reported to CMS, 2019-2025
38 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,971 · 2021: $8,146 · 2022: $26K · 2023: $44K · 2024: $49K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Consulting Fee: $14K · Food and Beverage: $5,553 · Travel and Lodging: $3,640 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,110.50 |
| Consulting Fee | $14,100.00 |
| Food and Beverage | $5,553.45 |
| Travel and Lodging | $3,640.38 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101,816.90 | 2019-2025 | |
| Allergan, INC. | $50,163.59 | 2019-2022 | |
| Galderma Laboratories, L.P. | $19,370.65 | 2019-2025 | Dysport, Nemluvio, Aklief |
| Pfizer INC. | $467.70 | 2019-2025 | |
| Janssen Biotech, INC. | $378.78 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $309.80 | 2019-2025 | |
| Genzyme Corporation | $286.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.33 | 2022-2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $235.80 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $178.07 | 2019-2023 | Taltz, Olumiant |
| Merz North America, INC. | $176.15 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $174.80 | 2019-2024 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $161.83 | 2019-2024 | Adbry |
| Ucb, INC. | $125.61 | 2020-2025 | Bimzelx |
| Amgen INC. | $122.85 | 2020-2023 | Otezla |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.